Preliminary Safety, Pharmacological and Efficacy Data from Patients with Relapsed or Refractory B-Cell Malignancies Treated with the ICP-248, a Next Generation BCL2 Inhibitor

被引：0
|
作者：
Yi, Shuhua [1 ,2 ,3 ]
Jin, Jie [4 ]
Zhou, Keshu [5 ]
Zhu, Huayuan [6 ]
Ma, Kate [7 ]
Jiang, Rili [8 ]
Wang, Weige [8 ]
Zhang, Bin [9 ]
Qiu, Lugui [1 ,2 ,3 ]
机构：
[1] Chinese Acad Med Sci & Peking Union Med Coll, Natl Clin Res Ctr Blood Dis, Haihe Lab Cell Ecosyst, State Key Lab Expt Hematol,Inst Hematol, Tianjin, Peoples R China
[2] Chinese Acad Med Sci & Peking Union Med Coll, Blood Dis Hosp, Tianjin, Peoples R China
[3] Tianjin Inst Hlth Sci, Tianjin, Peoples R China
[4] Zhejiang Univ, Affiliated Hosp 1, Sch Med, Hangzhou, Peoples R China
[5] Zhengzhou Univ, Henan Canc Hosp, Canc Hosp, Dept Hematol, Zhengzhou, Peoples R China
[6] Nanjing Med Univ, Jiangsu Prov Hosp, Affiliated Hosp 1, Dept Hematol, Nanjing, Peoples R China
[7] Beijing InnoCare Pharm Tech Co Ltd, Beijing, Peoples R China
[8] Beijing InnoCare Pharm Tech Co Ltd, Shanghai, Peoples R China
[9] InnoCare Pharma Ltd, Beijing, Peoples R China
来源：
BLOOD | 2023年 / 142卷
关键词：
D O I：
10.1182/blood-2023-182558
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [31] Phase 2 Study Evaluating the Efficacy and Safety of Parsaclisib in Patients with Relapsed or Refractory Mantle Cell Lymphoma Not Previously Treated with a BTK Inhibitor (CITADEL-205)
    Mehta, Amitkumar
    Trneny, Marek
    Walewski, Jan
    Ribrag, Vincent
    Dartigeas, Caroline
    Christensen, Jacob Haaber
    Pane, Fabrizio
    Rodriguez, Guillermo
    Taszner, Michal
    Venugopal, Parameswaran
    Zilioli, Vittorio Ruggero
    Zheng, Fred
    DeMarini, Douglas J.
    Jiang, Wei
    Zinzani, Pier Luigi
    BLOOD, 2020, 136
  • [32] Results From a Phase 1/2 Study of INCB050465, a Potent and Highly Selective PI3K delta Inhibitor, in Patients With Relapsed or Refractory B-Cell Malignancies
    Martin, Peter
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2018, 16 (04) : 9 - 10
  • [33] Efficacy and Safety of Umbralisib, Ublituximab (U2), and U2 Plus Bendamustine in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
    Burke, John M.
    Fonseca, Gustavo
    Jurczak, Wojciech
    Melear, Jason
    Islas-Ohlmayer, Miguel
    Reeves, James A.
    Venugopal, Parameswaran
    Wrobel, Tomasz
    Stevens, Don
    Pagel, John M.
    Goldschmidt, Jerome
    Miskin, Hari P.
    Sportelli, Peter
    O'Connor, Owen A.
    Ghosh, Nilanjan
    BLOOD, 2021, 138
  • [34] Safety and Efficacy of Blinatumomab in Japanese Adult and Pediatric Patients with Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia: Final Results from an Expansion Cohort
    Goto, Hiroaki
    Ogawa, Chitose
    Iida, Hiroatsu
    Horibe, Keizo
    Oh, Iekuni
    Takada, Satoru
    Maeda, Yoshinobu
    Minami, Hironobu
    Nakashima, Yasuhiro
    Morris, Joan D.
    Kormany, William
    Chen, Yuqi
    Miyamoto, Toshihiro
    ACTA HAEMATOLOGICA, 2022, 145 (06) : 592 - 602
  • [35] Efficacy and safety of lenalidomide oral monotherapy in patients with relapsed or refractory diffuse large B-cell lymphoma: Results from an international study (NHL-003)
    Czuczman, M. S.
    Vose, J.
    Zinzani, P.
    Reeder, C.
    Buckstein, R.
    Haioun, C.
    Bouabdallah, R.
    Polikoff, J.
    Ervin-Haynes, A.
    Witzig, T.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [36] Efficacy and Safety of Inotuzumab Ozogamicin in Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia Treated in the INO-VATE Trial: Outcomes by Salvage-Treatment Phase
    Jabbour, Elias
    Stelljes, Matthias
    Advani, Anjali
    DeAngelo, Daniel
    Goekbuget, Nicola
    Marks, David
    Stock, Wendy
    O'Brien, Susan
    Cassaday, Ryan
    Wang, Tao
    Neuhof, Alexander
    Vandendries, Erik
    Kantarjian, Hagop
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 : S191 - S191
  • [37] Preliminary Results from a Phase I, First-in-Human Study of YY-20394, a Highly Selective and Highly Potent PI3Kδ Inhibitor, in Patients with Relapsed or Refractory B-Cell Malignancies
    Qi, Junyuan
    Song, Yuqin
    Jiang, Bo
    Li, Jianyong
    Tu, Meifeng
    Ping, Lingyan
    Li, Zengjun
    Xu, Wei
    Zhu, Huayuan
    Zhu, Jun
    Bao, Hanying
    Xu, Zusheng
    Qiu, Lugui
    BLOOD, 2018, 132
  • [38] Monotherapy with Second-Generation BCL2 Inhibitor Sonrotoclax (BGB-11417) Is Well Tolerated with High Response Rates in Patients with Relapsed/Refractory Marginal Zone Lymphoma: Data from an Ongoing Phase 1 Study
    Tedeschi, Alessandra
    Cheah, Chan Yoon
    Opat, Stephen S.
    Verner, Emma
    Magnano, Laura
    Epperla, Narendranath
    Hilger, James
    Fang, Yiqian
    Simpson, David
    Guo, Haiyi
    Anderson, Mary Ann
    BLOOD, 2023, 142
  • [39] Interim Report from a Phase 2 Multicenter Study of Tazemetostat, an EZH2 Inhibitor: Clinical Activity and Favorable Safety in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
    Morschhauser, Franck
    Salles, Gilles
    Mckay, Pamela
    Tilly, Herve
    Schmitt, Anna
    Gerecitano, John
    Johnson, Peter
    Le Gouill, Steven
    Dickinson, Michael
    Fruchart, Christophe
    Lamy, Thierry
    Chaidos, Aristeidis
    Jurczak, Wojciech
    Opat, Stephen
    Radford, John
    Zinzani, Pier Luigi
    Assouline, Sarit
    Cartron, Guillaume
    Clawson, Alicia
    Picazio, Natasha
    Ribich, Scott
    Blakemore, Stephen
    Larus, John
    Miao, Harry
    Woodruff, Mark
    Ho, Peter
    Ribrag, Vincent
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 : S380 - S381
  • [40] Durable Efficacy and Manageable Safety in Patients Aged ≥75 Years With Relapsed/Refractory Large B-Cell Lymphoma (R/R LBCL) Treated With Tisagenlecleucel in the Real-World Setting
    Landsburg, Daniel J.
    Heim, Michael
    Moskop, Amy
    Foley, Stephen Ronan
    Hill, Brian T.
    Schofield, Grant
    Jacobson, Caron A.
    Jaglowski, Samantha
    Locke, Frederick L.
    Ram, Ron
    Riedell, Peter A.
    Shah, Gunjan L.
    Popplewell, Leslie L.
    Tiwari, Ranjan
    Lim, Stephen
    Maier, Harald
    Majdan, Marta
    Pasquini, Marcelo C.
    Frigault, Matthew J.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S471 - S471
12345